The Technical Analyst
Select Language :

Cabaletta Bio Inc [CABA]

Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cabaletta Bio Inc is listed at the NASDAQ Exchange

-4.35% $2.86

Last updated: 21 Jan 2022 @ 13:20 pm


FUNDAMENTALS
MarketCap: 81.03 mill
EPS: -1.660
P/E: 0.000
Earnings Date: Mar 14, 2022
SharesOutstanding: 28.33 mill
Avg Daily Volume: 0.616 mill
RATING 2022-01-20
B+
Buy
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debtn/an/an/an/an/an/a
DISCOUNTED CASH FLOW VALUE
$7.24
(153.18%) $4.38
Date: 2022-01-21

Insider Trading

Date Person Action Amount type
2022-01-18 Das Arun Buy 100 000 Stock Option (Right to Buy)
2022-01-18 Gerard Michael Buy 75 000 Stock Option (Right to Buy)
2022-01-18 Marda Anup Buy 135 000 Stock Option (Right to Buy)
2022-01-18 Binder Gwendolyn Buy 160 000 Stock Option (Right to Buy)
2022-01-18 Nichtberger Steven Buy 380 000 Stock Option (Right to Buy)
INSIDER POWER
19.53
Last 50 transactions
Buy: 8 460 345 | Sell: 6 632 440

Forecast: 14:58 - $2.87

Live Trading Signals (every 1 min)

Forecast 1: 13:28 - $2.84
Forecast 2: 14:18 - $2.87
Forecast 3: 14:58 - $2.87
SCORE
-10.00
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.86 (-4.35% )
Volume 0.0604 mill
Avg. Vol. 0.616 mill
% of Avg. Vol 9.81 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Cabaletta Bio Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Cabaletta Bio Inc

RSI

Intraday RSI14 chart for Cabaletta Bio Inc
The Live Chart for Cabaletta Bio Inc
Profile picture for
            Cabaletta Bio Inc

CABA

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 19 full-time employees. The firm is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The firm has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Last 10 Buy Signals
Date Signal @

Stock Peers

Company Price Change
CABA2.86-4.35%
ADMS8.220.00%
CHMA3.76-6.00%
CODX7.69-6.90%
IMCC2.30-7.63%
IMNM7.93-9.35%
OVID3.11-0.96%
PLXP5.94-3.57%
SRRA17.91-4.94%
TFFP6.48-6.36%
VINC7.013.09%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.